Histogen Inc. (HSTO): Price and Financial Metrics


Histogen Inc. (HSTO): $1.03

0.02 (+1.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HSTO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HSTO POWR Grades

  • Sentiment is the dimension where HSTO ranks best; there it ranks ahead of 98.09% of US stocks.
  • The strongest trend for HSTO is in Quality, which has been heading down over the past 121 days.
  • HSTO ranks lowest in Stability; there it ranks in the 2nd percentile.

HSTO Stock Summary

  • HSTO has a higher market value than only 0.73% of US stocks; more precisely, its current market capitalization is $4,528,065.
  • In terms of volatility of its share price, HSTO is more volatile than 97.65% of stocks we're observing.
  • HISTOGEN INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -164.22%, greater than the shareholder yield of only 3.76% of stocks in our set.
  • Stocks that are quantitatively similar to HSTO, based on their financial statements, market capitalization, and price volatility, are RNWK, SIGA, BJDX, NURO, and NAVB.
  • HSTO's SEC filings can be seen here. And to visit HISTOGEN INC's official web site, go to www.histogeninc.com.

HSTO Valuation Summary

  • HSTO's price/sales ratio is 1.2; this is 75% lower than that of the median Healthcare stock.
  • Over the past 114 months, HSTO's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for HSTO.

Stock Date P/S P/B P/E EV/EBIT
HSTO 2022-11-25 1.2 0.3 -0.4 0.5
HSTO 2022-11-23 1.1 0.2 -0.4 0.6
HSTO 2022-11-22 1.1 0.2 -0.4 0.6
HSTO 2022-11-21 1.1 0.2 -0.4 0.6
HSTO 2022-11-18 1.2 0.3 -0.4 0.5
HSTO 2022-11-17 1.2 0.3 -0.4 0.5

HSTO Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 29.12%.
  • The 2 year price growth rate now stands at -95.14%.
  • Its year over year revenue growth rate is now at 188.1%.
Over the past 33 months, HSTO's revenue has gone down $17,947,000.

The table below shows HSTO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.77 -9.962 -11.28
2022-06-30 4.356 -11.399 -11.525
2022-03-31 4.356 -11.265 -11.353
2021-12-31 1.032 -14.532 -14.95
2021-09-30 1.505 -15.888 -15.323
2021-06-30 1.409 -15.751 -14.731

HSTO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSTO has a Quality Grade of D, ranking ahead of 11.54% of graded US stocks.
  • HSTO's asset turnover comes in at 0.064 -- ranking 308th of 681 Pharmaceutical Products stocks.
  • PLXP, AGTC, and LPTX are the stocks whose asset turnover ratios are most correlated with HSTO.

The table below shows HSTO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.064 0.403 -1.400
2021-03-31 0.080 0.385 -2.095
2020-12-31 0.126 0.530 -2.520
2020-09-30 0.062 0.633 -4.218
2020-09-30 0.062 0.633 -4.218
2020-06-30 0.190 0.978 -6.396

HSTO Price Target

For more insight on analysts targets of HSTO, see our HSTO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.00 Average Broker Recommendation 1.25 (Strong Buy)

HSTO Stock Price Chart Interactive Chart >

Price chart for HSTO

HSTO Price/Volume Stats

Current price $1.03 52-week high $9.95
Prev. close $1.01 52-week low $0.90
Day low $0.99 Volume 57,400
Day high $1.05 Avg. volume 347,970
50-day MA $1.21 Dividend yield N/A
200-day MA $2.83 Market Cap 4.40M

Histogen Inc. (HSTO) Company Bio


Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.


HSTO Latest News Stream


Event/Time News Detail
Loading, please wait...

HSTO Latest Social Stream


Loading social stream, please wait...

View Full HSTO Social Stream

Latest HSTO News From Around the Web

Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments.

GlobeNewswire | November 10, 2022

Histogen GAAP EPS of -$1.01

Histogen press release (HSTO): Q3 GAAP EPS of -$1.01.Cash and cash equivalents - as of September 30, 2022, we had $14.6 million in cash and cash equivalents

Seeking Alpha | November 10, 2022

Histogen Inc. (NASDAQ: HSTO) Is Rated A Buy By Analysts.

In the latest trading session, 1.39 million Histogen Inc. (NASDAQ:HSTO) shares changed hands as the company’s beta touched 1.30. With the company’s most recent per share price at $1.54 changing hands around $0.54 or 54.74% at last look, the market valuation stands at $2.57M. HSTO’s current price is a discount, trading about -846.75% off its … Histogen Inc. (NASDAQ: HSTO) Is Rated A Buy By Analysts. Read More »

Marketing Sentinel | November 9, 2022

Histogen Inc. (HSTO) produces promising results

As of Tuesday, Histogen Inc.’s (NASDAQ:HSTO) stock closed at $2.22, up from $2.06 the previous day. While Histogen Inc. has overperformed by 7.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HSTO fell by -86.48%, with highs and lows ranging from $18.40 to $1.61, whereas the […]

US Post News | August 31, 2022

Histogen Inc.’s (NASDAQ: HSTO) Future In 2022

Histogen Inc. (NASDAQ:HSTO) shares, rose in value on Friday, 08/26/22, with the stock price down by -0.51% to the previous day’s close as strong demand from buyers drove the stock to $1.97. Actively observing the price movement in the last trading, the stock closed the session at $1.98, falling within a range of $1.93 and … Histogen Inc.’s (NASDAQ: HSTO) Future In 2022 Read More »

Stocks Register | August 27, 2022

Read More 'HSTO' Stories Here

HSTO Price Returns

1-mo -11.97%
3-mo -43.41%
6-mo -55.22%
1-year -87.94%
3-year -98.54%
5-year -99.87%
YTD -84.52%
2021 -56.11%
2020 -81.05%
2019 -76.88%
2018 -62.55%
2017 -12.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7997 seconds.